HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $200

Benzinga · 6d ago
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $185 to $200.